UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 155

Sortiert nach

Checkpoint inhibition in hematologic malignancies

Frontiers in oncology, 2023-10, Vol.13, p.1288172-1288172

2023

Link zum Volltext

Verfügbarkeit prüfen

Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Journal of clinical oncology, 2008-10, Vol.26 (30), p.4952-4957

2008

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

Frontiers in oncology, 2021-03, Vol.11, p.649209-649209

2021

Link zum Volltext

Verfügbarkeit prüfen

Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2013-08, Vol.27 (4), p.293-304

2013

Link zum Volltext

Verfügbarkeit prüfen

A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activation

PloS one, 2018-01, Vol.13 (1), p.e0190860

2018

Link zum Volltext

Verfügbarkeit prüfen

A Fermented Wheat Germ Extract Contains Protein Components Active against NSCLC Xenografts In Vivo

Current issues in molecular biology, 2023-08, Vol.45 (9), p.7087-7096

2023

Link zum Volltext

Verfügbarkeit prüfen

A Protective Role of Aryl Hydrocarbon Receptor Repressor in Inflammation and Tumor Growth

Cancers, 2019-04, Vol.11 (5), p.589

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML

Leukemia research reports, 2023-01, Vol.19, p.100374-100374, Article 100374

2023

Link zum Volltext

Verfügbarkeit prüfen

Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate

Molecular medicine (Cambridge, Mass.), 2016-01, Vol.22 (1), p.632-642

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, Biodistribution, and Pharmacokinetics of CD22-Targeted Pegylated Liposomal Doxorubicin in a B-cell Non-Hodgkin's Lymphoma Xenograft Mouse Model

Clinical cancer research, 2010-05, Vol.16 (10), p.2760-2768

2010

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis and classification of autoimmune hemolytic anemia

Autoimmunity reviews, 2014-04, Vol.13 (4), p.560-564

2014

Link zum Volltext

Verfügbarkeit prüfen

Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma

American journal of hematology, 2017-10, Vol.92 (10), p.E575-E583

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial

British journal of haematology, 2011-08, Vol.154 (4), p.533-535

2011

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment

Journal of rheumatology, 2005-11, Vol.32 (11), p.2109

2005

Link zum Volltext

Verfügbarkeit prüfen

A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model

Cancer Immunology, Immunotherapy, 2023-09, Vol.72 (9), p.2939-2948

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of the combination of ibrutinib and lenalidomide of the treatment of patients with MDS who have failed standard therapy or who are unfit for or refuse standard therapy

Leukemia research, 2022-11, Vol.122, p.106947-106947, Article 106947

2022

Link zum Volltext

Verfügbarkeit prüfen

Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non‐Hodgkin lymphoma

British journal of haematology, 2014-05, Vol.165 (3), p.375-381

2014

Link zum Volltext

Verfügbarkeit prüfen

Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma

Clinical cancer research, 2021-09, Vol.27 (17), p.4726-4736

2021

Link zum Volltext

Verfügbarkeit prüfen

Applications of One-Bead One-Compound Combinatorial Libraries and Chemical Microarrays in Signal Transduction Research

Accounts of chemical research, 2003-06, Vol.36 (6), p.370-377

2003

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

Clinical cancer research, 2019-12, Vol.25 (23), p.7004-7013

2019

Link zum Volltext

Verfügbarkeit prüfen

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

British journal of haematology, 2009-05, Vol.145 (3), p.344-349

2009

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma

Oncoimmunology, 2012-12, Vol.1 (9), p.1469-1475

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 155

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(153)
Mit Volltextzugriff
(145)

Publikationsform

Artikel
(154)
magazinearticle
(1)

Sprache

Englisch
(155)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Science & Technology
(84)
Life Sciences & Biomedicine
(81)
Humans
(69)
Oncology
(41)
Hematology
(38)
Female
(37)
Biological And Medical Sciences
(31)
Male
(27)
Medical Sciences
(27)
Animals
(26)
Aged
(24)
Middle Aged
(23)
Mice
(22)
Adult
(20)
Cd22
(17)
Immunology
(17)
Lymphoma
(17)
Hematologic And Hematopoietic Diseases
(16)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(16)
Treatment Outcome
(16)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Checkpoint inhibition in hematologic malignancies

Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)

Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook

A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activation

A Fermented Wheat Germ Extract Contains Protein Components Active against NSCLC Xenografts In Vivo

A Protective Role of Aryl Hydrocarbon Receptor Repressor in Inflammation and Tumor Growth

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML

Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate

Efficacy, Biodistribution, and Pharmacokinetics of CD22-Targeted Pegylated Liposomal Doxorubicin in a B-cell Non-Hodgkin's Lymphoma Xenograft Mouse Model

Diagnosis and classification of autoimmune hemolytic anemia

Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial

Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment

A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model

Phase I trial of the combination of ibrutinib and lenalidomide of the treatment of patients with MDS who have failed standard therapy or who are unfit for or refuse standard therapy

Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non‐Hodgkin lymphoma

Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma

Applications of One-Bead One-Compound Combinatorial Libraries and Chemical Microarrays in Signal Transduction Research

A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma

Suchergebnisse filtern